• Explore /
  • Poster
  • / Sorafenib and irinotecan combination for pre-treated RAS-mutated metastatic colorectal cancer patients: A multicentre randomized phase II trial (NEXIRI 2).

Sorafenib and irinotecan combination for pre-treated RAS-mutated metastatic colorectal cancer patients: A multicentre randomized phase II trial (NEXIRI 2).

Abstract Poster

Authors

null

Emmanuelle Samalin

Institut Régional du Cancer de Montpellier, Montpellier, France

Emmanuelle Samalin , Christelle De La Fouchardiere , Simon Thezenas , Valérie Boige , Hélène Senellart , Rosine Guimbaud , Julien Taïeb , Eric Francois , Marie-Pierre Galais , Antoine Adenis , Astrid Lievre , Jean-François Seitz , Jean-Philippe Metges , Olivier Bouche Sr., Marianne Fonck , Frédéric Di Fiore , Pascal Artru , Thomas Aparicio , Thibault Mazard , Marc Ychou

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01715441

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr 635)

DOI

10.1200/jco.2016.34.4_suppl.635

Abstract #

635

Poster Bd #

G18

Abstract Disclosures

Similar Posters

First Author: Emmanuelle Samalin

First Author: Chiara Cremolini

First Author: Hirokazu Shoji

Poster

2014 ASCO Annual Meeting

Phase II study of single-agent cetuximab in <i>KRAS</i> G13D mutant metastatic colorectal cancer (mCRC).

Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (mCRC).

First Author: Marta Schirripa